RXO INC (RXO) Fundamental Analysis & Valuation

NYSE:RXO • US74982T1034

Current stock price

18.7 USD
+0.72 (+4%)
At close:
18.7557 USD
+0.06 (+0.3%)
After Hours:

This RXO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. RXO Profitability Analysis

1.1 Basic Checks

  • RXO had negative earnings in the past year.
  • In the past year RXO had a positive cash flow from operations.
  • In multiple years RXO reported negative net income over the last 5 years.
  • Of the past 5 years RXO 4 years had a positive operating cash flow.
RXO Yearly Net Income VS EBIT VS OCF VS FCFRXO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M 300M

1.2 Ratios

  • RXO has a worse Return On Assets (-3.05%) than 66.67% of its industry peers.
  • RXO has a worse Return On Equity (-6.49%) than 64.29% of its industry peers.
Industry RankSector Rank
ROA -3.05%
ROE -6.49%
ROIC N/A
ROA(3y)-3.78%
ROA(5y)0.09%
ROE(3y)-7.94%
ROE(5y)1.18%
ROIC(3y)N/A
ROIC(5y)N/A
RXO Yearly ROA, ROE, ROICRXO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 10 -10

1.3 Margins

  • RXO has a worse Gross Margin (16.39%) than 71.43% of its industry peers.
  • RXO's Gross Margin has declined in the last couple of years.
  • RXO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 16.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.2%
RXO Yearly Profit, Operating, Gross MarginsRXO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 5 -5 10 15

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. RXO Health Analysis

2.1 Basic Checks

  • RXO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, RXO has more shares outstanding
  • Compared to 5 years ago, RXO has more shares outstanding
  • Compared to 1 year ago, RXO has a worse debt to assets ratio.
RXO Yearly Shares OutstandingRXO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 50M 100M 150M
RXO Yearly Total Debt VS Total AssetsRXO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • RXO has an Altman-Z score of 2.71. This is not the best score and indicates that RXO is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of RXO (2.71) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.25 indicates that RXO is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.25, RXO is in line with its industry, outperforming 57.14% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z 2.71
ROIC/WACCN/A
WACC10.49%
RXO Yearly LT Debt VS Equity VS FCFRXO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • RXO has a Current Ratio of 1.27. This is a normal value and indicates that RXO is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.27, RXO is in line with its industry, outperforming 59.52% of the companies in the same industry.
  • A Quick Ratio of 1.27 indicates that RXO should not have too much problems paying its short term obligations.
  • RXO has a Quick ratio (1.27) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.27
RXO Yearly Current Assets VS Current LiabilitesRXO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. RXO Growth Analysis

3.1 Past

  • RXO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -145.45%.
  • The Revenue has grown by 26.20% in the past year. This is a very strong growth!
  • The Revenue has been growing by 11.33% on average over the past years. This is quite good.
EPS 1Y (TTM)-145.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.67%
Revenue 1Y (TTM)26.2%
Revenue growth 3Y6.18%
Revenue growth 5Y11.33%
Sales Q2Q%-11.88%

3.2 Future

  • Based on estimates for the next years, RXO will show a very strong growth in Earnings Per Share. The EPS will grow by 155.84% on average per year.
  • Based on estimates for the next years, RXO will show a quite strong growth in Revenue. The Revenue will grow by 9.55% on average per year.
EPS Next Y90.24%
EPS Next 2Y212.21%
EPS Next 3Y155.84%
EPS Next 5YN/A
Revenue Next Year-0.55%
Revenue Next 2Y3%
Revenue Next 3Y4.63%
Revenue Next 5Y9.55%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
RXO Yearly Revenue VS EstimatesRXO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B 8B 10B
RXO Yearly EPS VS EstimatesRXO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 0 0.5 1

More info and screens

Find the best growth stocksShow best growing peers

1

4. RXO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RXO. In the last year negative earnings were reported.
  • Also next year RXO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXO Price Earnings VS Forward Price EarningsRXO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -1K -2K -3K

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RXO indicates a slightly more expensive valuation: RXO is more expensive than 71.43% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 30.72
RXO Per share dataRXO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • RXO's earnings are expected to grow with 155.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y212.21%
EPS Next 3Y155.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RXO Dividend Analysis

5.1 Amount

  • RXO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RXO Fundamentals: All Metrics, Ratios and Statistics

RXO INC

NYSE:RXO (4/17/2026, 8:04:00 PM)

After market: 18.7557 +0.06 (+0.3%)

18.7

+0.72 (+4%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupTransportation
GICS IndustryGround Transportation
Earnings (Last)02-06
Earnings (Next)05-07
Inst Owners108.53%
Inst Owner Change0%
Ins Owners0.84%
Ins Owner Change2.22%
Market Cap3.08B
Revenue(TTM)5.74B
Net Income(TTM)-100.00M
Analysts66.92
Price Target16.34 (-12.62%)
Short Float %8.54%
Short Ratio5.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-75.97%
Min EPS beat(2)-79.64%
Max EPS beat(2)-72.3%
EPS beat(4)1
Avg EPS beat(4)-27.69%
Min EPS beat(4)-79.64%
Max EPS beat(4)101.04%
EPS beat(8)5
Avg EPS beat(8)-6.09%
EPS beat(12)8
Avg EPS beat(12)38.1%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2%
Min Revenue beat(2)-2.2%
Max Revenue beat(2)-1.8%
Revenue beat(4)0
Avg Revenue beat(4)-2.86%
Min Revenue beat(4)-5.04%
Max Revenue beat(4)-1.8%
Revenue beat(8)1
Avg Revenue beat(8)-1.36%
Revenue beat(12)2
Avg Revenue beat(12)-2.06%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.61%
EPS NQ rev (1m)-0.84%
EPS NQ rev (3m)-105.48%
EPS NY rev (1m)-136.02%
EPS NY rev (3m)-102.85%
Revenue NQ rev (1m)-0.07%
Revenue NQ rev (3m)-5.38%
Revenue NY rev (1m)-0.1%
Revenue NY rev (3m)-3.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.54
P/FCF N/A
P/OCF 60.39
P/B 2
P/tB N/A
EV/EBITDA 30.72
EPS(TTM)-0.05
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)0.31
OCFY1.66%
SpS34.86
BVpS9.36
TBVpS-0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -3.05%
ROE -6.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 16.39%
FCFM N/A
ROA(3y)-3.78%
ROA(5y)0.09%
ROE(3y)-7.94%
ROE(5y)1.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.2%
F-Score5
Asset Turnover1.75
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA 3.55
Cap/Depr 50.86%
Cap/Sales 1.03%
Interest Coverage N/A
Cash Conversion 46.79%
Profit Quality N/A
Current Ratio 1.27
Quick Ratio 1.27
Altman-Z 2.71
F-Score5
WACC10.49%
ROIC/WACCN/A
Cap/Depr(3y)66.04%
Cap/Depr(5y)62.51%
Cap/Sales(3y)1.22%
Cap/Sales(5y)1.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-145.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.67%
EPS Next Y90.24%
EPS Next 2Y212.21%
EPS Next 3Y155.84%
EPS Next 5YN/A
Revenue 1Y (TTM)26.2%
Revenue growth 3Y6.18%
Revenue growth 5Y11.33%
Sales Q2Q%-11.88%
Revenue Next Year-0.55%
Revenue Next 2Y3%
Revenue Next 3Y4.63%
Revenue Next 5Y9.55%
EBIT growth 1Y-123.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year133.6%
EBIT Next 3Y84.84%
EBIT Next 5Y60.59%
FCF growth 1Y85.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y525%
OCF growth 3Y-45.21%
OCF growth 5Y15.33%

RXO INC / RXO Fundamental Analysis FAQ

What is the fundamental rating for RXO stock?

ChartMill assigns a fundamental rating of 2 / 10 to RXO.


What is the valuation status for RXO stock?

ChartMill assigns a valuation rating of 1 / 10 to RXO INC (RXO). This can be considered as Overvalued.


How profitable is RXO INC (RXO) stock?

RXO INC (RXO) has a profitability rating of 1 / 10.


Can you provide the financial health for RXO stock?

The financial health rating of RXO INC (RXO) is 3 / 10.